comparemela.com
Home
Live Updates
Aimee Keegan - Breaking News
Pages:
Latest Breaking News On - Aimee keegan - Page 1 : comparemela.com
NATALEE Data Shows Ribociclib Reduces Risk of Recurrence for High-Risk Node-Negative Early Breast Cancer
The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.
United states
Sebastian kaulitzki
Denisea yardley
Jeff legos
Aimee keegan
Sarah cannon research institute
Breast cancer research executive committee
Global head of oncology development
European medicines agency
American society of clinical oncology
Breast cancer research
Pharmacy times
Clinical oncology
Annual meeting
Global head
Oncology development
NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer
Aimee Keegan, PharmD, BCOP, discusses key unmet needs that the NATALEE trial addresses for patients with HR+/HER2- early breast cancer.
Aimee keegan
Peer exchange
Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer
Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.
Aimee keegan
Peer exchange
Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer
Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.
Aimee keegan
Peer exchange
vimarsana © 2020. All Rights Reserved.